Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15928055 | 0.93 | LMNA (0.33) | LOXL2LMNARECQLALDH1A1MAPT | |
| SCHEMBL15929407 | 0.89 | LMNA (0.35) | LOXL2LMNARECQLALDH1A1MAPT | |
| SCHEMBL15928042 | 0.86 | HDAC3 (0.31) | LMNARECQLCYP2C9 | |
| SCHEMBL15929441 | 0.82 | TMEM97 (0.36) | LMNARECQLALDH1A1MAPTCNR2 | |
| SCHEMBL22236871 | 0.81 | MEN1 (0.38) | LMNAALDH1A1MAPT | |
| SCHEMBL15929436 | 0.77 | DNM1 (0.32) | — | |
| SCHEMBL15929461 | 0.76 | LOXL2 (0.41) | LOXL2LMNARECQLALDH1A1MAPT | |
| SCHEMBL15929435 | 0.74 | MGLL (0.45) | LMNAALDH1A1MAPT | |
| SCHEMBL19099646 | 0.72 | LOXL2 (0.39) | LOXL2LMNARECQLALDH1A1MAPT | |
| SCHEMBL22236839 | 0.72 | MEN1 (0.43) | LMNAALDH1A1MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542267-B2 | Cryptate compounds | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2023-01-03 | — | — | US | disclosed |
| US-11535623-B2 | Cryptate compounds | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2022-12-27 | — | — | US | disclosed |
| US-20200308182-A1 | CRYPTATE COMPOUNDS | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2020-10-01 | — | — | US | disclosed |
| US-20200308183-A1 | CRYPTATE COMPOUNDS | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2020-10-01 | — | — | US | disclosed |
| US-10717741-B2 | Cryptate compounds | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2020-07-21 | — | — | US | disclosed |
| US-20140219915-A1 | CRYPTATE COMPOUNDS | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308183-A1 | CRYPTATE COMPOUNDS | HCCS, SQOR, NQO1 | LOXL2 3192/4885LMNA 2573/4885RECQL 1980/4885 |
| US-20140219915-A1 | CRYPTATE COMPOUNDS | HCCS, SQOR, NQO1 | LOXL2 3192/4885LMNA 2573/4885RECQL 1980/4885 |
| US-11542267-B2 | Cryptate compounds | HCCS, SQOR, NQO1 | LOXL2 3192/4885LMNA 2573/4885RECQL 1980/4885 |
| US-20200308182-A1 | CRYPTATE COMPOUNDS | HCCS, SQOR, NQO1 | LOXL2 3192/4885LMNA 2573/4885RECQL 1980/4885 |
| US-10717741-B2 | Cryptate compounds | HCCS, SQOR, NQO1 | LOXL2 3192/4885LMNA 2573/4885RECQL 1980/4885 |
| US-11535623-B2 | Cryptate compounds | HCCS, SQOR, NQO1 | LOXL2 3192/4885LMNA 2573/4885RECQL 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.